Search
A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)
Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25%...
Mar 10
BioVenture VoiCes Episode 14: Aditum Bio's Joe Jimenez
Joe Jimenez describes the career path in consumer products that led him to pharma, his time running Novartis, and the idea to co-found...
Mar 10
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus,...
Mar 6
Korro Bio's Ram Aiyar and Novo Nordisk's Uli Stilz discuss their RNA editing collaboration, the field of genetic medicine, and the future of drug discovery
Ram Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their...
Mar 5
Biotech CEO Sisterhood: Vir's CEO Marianne De Backer describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO deal
Interviewed by Sisterhood editorial board member Grace Colón, Marianne De Backer advocates for the importance of getting experience in a...
Mar 3
HSBC's Capital Markets Investment Team talks about getting the most out of your company's cash management
Meet the team at HSBC that helps biopharma CFOs (and from other industries) with their cash/liquidity investing. #sponsored
Mar 3
On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science
Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the...
Feb 28
Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL
CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program...
Feb 26
Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them
Co-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug...
Feb 26
With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline
CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese...
Feb 26
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
Feb 24
Devan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and more
Devan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to...
Feb 24
BioVenture VoiCes Episode 13: Civilization Ventures' Shahram Seyedin-Noor
Shahram describes his upbringing as a refugee from Iran, his early career in law and banking, and how his initial experience in the tech...
Feb 23
Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK
CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy...
Feb 21
Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development
CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead...
Feb 21
With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space
Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as...
Feb 20
Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome
He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's...
Feb 18
The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy
Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations...
Feb 18
Biotech CEO Sisterhood: Serial entrepreneur Sheila Mikhail on overcoming obstacles and getting the job done, including multiple major acquisitions in her own career
Interviewed by ReCode Therapeutics' CEO Shehnaaz Suliman, she describes the journey of co-founding companies including AskBio, Bamboo...
Feb 17
Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success
She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory...
Feb 13
.png){kind=logo}
